OKYO (OKYO Pharma) ROE % Adjusted to Book Value: 0.00% (As of Sep. 2025)

OKYO Pharma OKYO +8.70% 23 ROE % Adjusted to Book Value is 0.00% as of Sep. 2025. GuruFocus rates OKYO with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

OKYO Pharma's ROE % for the quarter that ended in Sep. 2025 was 0.00%. OKYO Pharma's PB Ratio for the quarter that ended in Sep. 2025 was N/A. OKYO Pharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 was N/A.

OKYO Pharma ROE % Adjusted to Book Value Related Terms

OKYO Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma ROE % Adjusted to Book Value Chart

OKYO Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.00

OKYO Pharma Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

OKYO vs ENTX, HRTX, RANI: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, OKYO Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's ROE % Adjusted to Book Value falls into.

Save Embed

23GF Score

OKYO Pharma Ltd OKYO

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

OKYO Pharma ROE % Adjusted to Book Value Calculation

OKYO Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

OKYO Pharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 0.00% mean?

OKYO Pharma (OKYO) has a ROE % Adjusted to Book Value of 0.00% as of Sep. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OKYO Pharma and its competitors.

Is OKYO Pharma's ROE % Adjusted to Book Value too high?

OKYO Pharma's current ROE % Adjusted to Book Value is 0.00%. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.

How does OKYO Pharma's ROE % Adjusted to Book Value compare to ENTX and HRTX?

OKYO Pharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is OKYO Pharma stock overvalued right now?

OKYO Pharma (OKYO) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For OKYO Pharma (OKYO), the current ROE % Adjusted to Book Value is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies ENTX HRTX RANI IBIO RNTX OSTX EDSA ACET CRDF MAIA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ

Website https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

23GF Score

Get the complete analysis for OKYO

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.75

Price

View OKYO Analysis

See ROE % Adjusted to Book Value data for all stocks →